Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 23 , ISSUE 7 ( July, 2019 ) > List of Articles

BRIEF COMMUNICATION

Therapeutic Plasma Exchange Practices in Intensive Care Unit

Rema Menon, Ramesh Venkatraman, Pratheema Ramachandran

Keywords : Apheresis, Crystalloids, Plasma, Plasmapheresis, Therapeutic plasma exchange

Citation Information : Menon R, Venkatraman R, Ramachandran P. Therapeutic Plasma Exchange Practices in Intensive Care Unit. Indian J Crit Care Med 2019; 23 (7):336-338.

DOI: 10.5005/jp-journals-10071-23209

License: CC BY-NC 4.0

Published Online: 01-12-2018

Copyright Statement:  Copyright © 2019; The Author(s).


Abstract

Objective: To observe the indications, practices and outcome of therapeutic plasma exchange (TPE) in a tertiary care ICU. Materials and Methods: The study involves retrospective analysis of 56 patients who underwent TPE between May 2011 and August 2013. Data relating to demographics, diagnosis, category of indication, number of sessions, volume and type of replacement solutions were collected. Results: Category I indications were 50%, with a mean of 3.32 sessions per patient. Per session volume exchanged was 9775.1 ± 11812.9 mL and replacement volume was 7414 ± 6993.03 mL. Fresh frozen plasma (FFP), crystalloids, cryopoorplasma and PRBC constituted 62.9%, 22%, 9.9% and 5.3% of volume replacement, respectively. TPE was terminated in three patients for Transfusion Associated Acute Lung Injury (TRALI), hypotension and cardiac arrest respectively. Clinical improvement was noted in 82% of patients and overall mortality rate was 12.5%. Conclusion: TPE is feasible and well tolerated in ICU with favorable disease resolution and outcome. Common indications included sickle cell and myasthenia crisis and blood products were the most commonly used for volume replacement.


PDF Share
  1. Dada MA, Kaplan AA. Plasmapheresis treatment in Guillain-Barre syndrome: potential benefit over IVIg in patients with axonal involvement. Ther Apher Dial 2004;8:409–412.
  2. The Utility of Therapeutic Plasmapheresis for Neurological Disorders National Institutes of Health Consensus Development Conference Statement, 1986.
  3. American Society For Aphaeresis (ASFA) 2010 guidelines.
  4. McLeod BC. Introduction to the third special issue: clinical applications of therapeutic apheresis. J Clin Apher 2000;15:1–5.
  5. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005;5:145–148.
  6. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143–146.
  7. Kaynar L, Altuntas F, Aydogdu I, Turgut B, Kocyigit I, Hacioglu SK et al. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci 2008;38:109–115.
  8. Kaplan AA. A simple and accurate method for prescribing plasma exchange. ASAIO Trans 1990;36:M597–M599.
  9. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 1987;22:753–761.
  10. Kfoury Baz EM, Khatib MF, Mahfouz RA, Jamaleddine GW. Deterioration of gas exchange in patients with severe thrombotic thrombocytopenic purpura with respiratory failure during therapeutic plasma exchange. J Clin Apher. 2001;16:143–147.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.